Medicare Part D drugs starting with X
32 drugs start with X; 13 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Xarelto in 2024: $6.2 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with X?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Xalkori (crizotinib) | 100% | Tier 5 | $59 million |
| Xarah Fe (ethinyl estradiol / norethindrone acetate) | 83.5% | Tier 2 | no 2024 match |
| Xarelto (rivaroxaban) | 100% | Tier 3 | $6.2 billion |
| Xatmep (methotrexate) | 95.4% | Tier 4 | $246 thousand |
| Xcopri (cenobamate) | 100% | Tier 4 | $165 million |
| Xdemvy (lotilaner) | 100% | Tier 5 | $114 million |
| Xeljanz (tofacitinib) | 61.1% | Tier 5 | $864 million |
| Xelria Fe (ethinyl estradiol / norethindrone) | 70% | Tier 4 | no 2024 match |
| Xelstrym (dextroamphetamine) | under 0.1% | Tier 2 | $200 thousand |
| Xenazine (tetrabenazine) | 0.2% | Tier 1 | $6 million |
| Xerese (acyclovir / hydrocortisone) | 0.4% | Tier 5 | $577 thousand |
| Xermelo (telotristat ethyl) | 100% | Tier 5 | $24 million |
| Xgeva (denosumab) | 31.8% | Tier 5 | $56 million |
| Xhance (fluticasone propionate) | 33% | Tier 4 | $20 million |
| Xifaxan (rifaximin) | 100% | Tier 5 | $1.2 billion |
| Xigduo (dapagliflozin / metformin hydrochloride) | 93.1% | Tier 3 | $204 million |
| Xiidra (lifitegrast) | 71% | Tier 3 | $505 million |
| Xofluza (baloxavir marboxil) | 41.3% | Tier 4 | $1 million |
| Xolair (omalizumab) | 100% | Tier 5 | $313 million |
| Xolremdi (mavorixafor) | 20.4% | Tier 5 | no 2024 match |
| Xopenex (levalbuterol) | 2.1% | Tier 4 | $1 million |
| Xospata (gilteritinib) | 100% | Tier 5 | $106 million |
| Xpovio (selinexor) | 100% | Tier 5 | $98 million |
| Xromi (hydroxyurea) | 2.8% | Tier 4 | no 2024 match |
| Xtampza (oxycodone) | 18.3% | Tier 3 | $233 million |
| Xtandi (enzalutamide) | 100% | Tier 5 | $3.4 billion |
| Xtrenbo (denosumab-qbde) | 12.8% | Tier 4 | no 2024 match |
| Xulane (ethinyl estradiol / norelgestromin) | 90.6% | Tier 3 | $675 thousand |
| Xultophy (insulin degludec / liraglutide) | 33.7% | Tier 3 | $91 million |
| Xyosted (testosterone enanthate) | 0.6% | Tier 3 | $29 million |
| Xyrem (sodium oxybate) | 0.8% | Tier 5 | $70 million |
| Xywav | 2.5% | Tier 5 | $211 million |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans